


AMENDMENT TO THE CLAIMS

This listing of the claims replaces all prior versions and listings in the application.

1-20. (Canceled)

21. (Currently amended) A compound of formula (I)



(I)


wherein

R is pyridyl, optionally mono- or disubstituted independently by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, trihalogenomethyl, methylthio, nitro, cyano, C₂₋₅ alkoxy carbonyl or carboxamido;

R_{1a}-CH₂ where R_{1a} is pyridyl, optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylendioxy, halogen, trihalogenomethyl, nitro or cyano; or


R_{1b}-CO, where R_{1b} is pyridyl, optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylendioxy, halogen, trihalogenomethyl, nitro or cyano; or R_{1b} is piperidino;

B is a group of formula (1), (2), (3), or (4)



and

Z is a group of formula (A), (B), (C), (D), (E), or (F);



or a salt, ~~isomer~~, ~~tautomer~~, or hydrate thereof.

22. (Canceled).

23. (Currently amended) The compound according to claim 21 wherein

R is pyridyl, optionally independently mono- or disubstituted with C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, trihalogenomethyl, methylthio, nitro, or cyano;

R_{1a}-CH₂, where R_{1a} is pyridyl, optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylendioxy, halogen, trihalogenomethyl, nitro or cyano; or

R_{1b}-CO where R_{1b} is pyridyl, optionally independently substituted with one or more C₁₋₄ alkyl, C₁₋₄ alkoxy, alkylendioxy, halogen, trihalogenomethyl, nitro or cyano; or R_{1b} is piperidino;

or a salt, ~~isomer, tautomer~~, or hydrate thereof.

24. (Currently amended) The compound according to claim 21 wherein

R is pyridyl, optionally independently mono- or disubstituted with C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro, cyano, C₂₋₅ alkoxy carbonyl or carboxamido;

or

R_{1b}CO where R_{1b} is piperidino; and

Z is a group of formula (A) or formula (B);

or a salt, ~~isomer, tautomer~~, or hydrate thereof.

25. (Currently amended) The compound according to claim 24 wherein

R is pyridyl, optionally independently mono- or disubstituted with C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro, or cyano;

or

R_{1b}CO where R_{1b} is piperidino;

or a salt, ~~isomer, tautomer~~, or hydrate thereof.

26. (Currently amended) The compound according to claim 25 wherein R is pyridyl, substituted with nitro or cyano, and B is a group of formula (1) or (2); or a salt, ~~isomer, tautomer~~, or hydrate thereof.

27. (Previously presented.) A compound selected from the group consisting of:

(4*R*)-3-(2-{[8-(5-Cyanopyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]-*exo*-amino} acetyl)thiazolidine-4-carbonitrile;

(4*R*)-3-(2-{[8-(5-Cyanopyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]-*endo*-amino} acetyl)thiazolidine-4-carbonitrile;

and

(2*S*)-1-(2- {[8-(5-Nitropyridin-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]-*exo*-amino} acetyl)pyrrolidine-2-carbonitrile;
or a salt, or hydrate thereof.

28. (Currently amended) A pharmaceutical composition comprising a compound according to claim 21 or a pharmaceutically acceptable salt, ~~isomer, tautomer~~, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

29. (Canceled)

30. (Currently amended) A pharmaceutical composition comprising a compound according to claim 23 or a pharmaceutically acceptable salt, ~~isomer, tautomer~~, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.


31. (Currently amended) A pharmaceutical composition comprising a compound according to claim 24 or a pharmaceutically acceptable salt, ~~isomer, tautomer~~, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

32. (Currently amended) A pharmaceutical composition comprising a compound according to claim 25 or a pharmaceutically acceptable salt, ~~isomer, tautomer~~, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

33. (Currently amended) A pharmaceutical composition comprising a compound according to claim 26 or a pharmaceutically acceptable salt, ~~isomer, tautomer~~, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.


34. (Currently amended) A pharmaceutical composition comprising a compound according to claim 27 or a pharmaceutically acceptable salt, or hydrate thereof, together with a pharmaceutically acceptable support material or diluent.

35. (Previously presented.) A process for preparing the compound according to claim 21 comprising reacting a compound of formula (II)



(II)

with a compound of formula (III)



wherein in the above formulas R, B, and Z are as defined in claim 21.

36-45. (Canceled)